Low levels of the vascular endothelial growth factor in CSF from early ALS patients
- 8 June 2004
- journal article
- Published by Wolters Kluwer Health in Neurology
- Vol. 62 (11) , 2127-2129
- https://doi.org/10.1212/01.wnl.0000129913.44351.a3
Abstract
Deletion of the hypoxia-response element in the vascular endothelial growth factor (VEGF) promoter causes motor neuron degeneration in a mouse model. “At-risk” haplotypes with low circulating VEGF levels have been demonstrated in humans. Here the authors report low VEGF levels in the CSF of ALS patients during their first year of the disease, independently of VEGF promoter polymorphism. This finding early in ALS patients suggests a possible role for VEGF gene regulation in the pathogenesis of ALS.Keywords
This publication has 9 references indexed in Scilit:
- Coordinate Activation of HIF-1 and NF-κB DNA Binding and COX-2 and VEGF Expression in Retinal Cells by HypoxiaInvestigative Opthalmology & Visual Science, 2003
- VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic deathNature Genetics, 2003
- TH2 Cytokine-enhanced and TGF-β-enhanced vascular endothelial growth factor production by cultured human airway smooth muscle cells is attenuated by IFN-γ and corticosteroidsJournal of Allergy and Clinical Immunology, 2003
- VEGF is increased in serum but not in spinal cord from patients with amyotrophic lateral sclerosisNeuroReport, 2002
- Increased levels of the pro-inflammatory prostaglandin PGE2 in CSF from ALS patientsNeurology, 2002
- Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degenerationNature Genetics, 2001
- Pitfalls in the Measurement of Circulating Vascular Endothelial Growth FactorClinical Chemistry, 2001
- Expression of hypoxia-inducible factor 1: mechanisms and consequencesPublished by Elsevier ,1999
- Increased 3‐nitrotyrosine in both sporadic and familial amyotrophic lateral sclerosisAnnals of Neurology, 1997